92 related articles for article (PubMed ID: 12101692)
1. [Amrubicin].
Shimizu T; Takada M; Yana T; Fukuoka M
Nihon Rinsho; 2002 May; 60 Suppl 5():374-7. PubMed ID: 12101692
[No Abstract] [Full Text] [Related]
2. [New anthracycline analogues in the treatment of lung cancer].
Ueoka H; Ohnoshi T; Kimura I
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2146-9. PubMed ID: 1332624
[TBL] [Abstract][Full Text] [Related]
3. [Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline].
Hanada M; Noguchi T; Murayama T
Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):141-50. PubMed ID: 12890900
[TBL] [Abstract][Full Text] [Related]
4. Amrubicin for the treatment of advanced lung cancer.
Kurata T
Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):171-80. PubMed ID: 19239396
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.
Kramer BS; Birch R; Gockerman JP; Greco A; Prestridge K
Cancer Treat Rep; 1986 Jun; 70(6):803-4. PubMed ID: 3015404
[No Abstract] [Full Text] [Related]
6. [Chemotherapy for lung cancer].
Kurata T; Fukuoka M
Nihon Rinsho; 2002 May; 60 Suppl 5():309-16. PubMed ID: 12101679
[No Abstract] [Full Text] [Related]
7. Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?
Bahl A; Falk S
Br J Cancer; 2001 May; 84(9):1143-5. PubMed ID: 11336462
[No Abstract] [Full Text] [Related]
8. Phase II clinical trial with bisantrene in patients with advanced refractory small cell lung cancer.
Myers JW; Von Hoff DD; Clark GM; Coltman CA
Cancer Treat Rep; 1984 Jun; 68(6):927-8. PubMed ID: 6329511
[No Abstract] [Full Text] [Related]
9. Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.
Conley BA; Hornedo J; Abrams J; Eisenberger M; Hiponia D; Aisner J; Van Echo DA
Cancer Treat Rep; 1987 Sep; 71(9):861-2. PubMed ID: 3040246
[No Abstract] [Full Text] [Related]
10. [Taxol in bronchial carcinoma].
Gatzemeier U
Med Klin (Munich); 1996 Dec; 91 Suppl 2():1-6. PubMed ID: 9082171
[No Abstract] [Full Text] [Related]
11. [Results of a phase I-II clinical trial of Emoxyl, a novel antineoplastic anthracycline].
Korman DB; Mikaélian SG; Boronovskaia LE; Maslova IA
Vopr Onkol; 2004; 50(2):202-7. PubMed ID: 15176224
[TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
[TBL] [Abstract][Full Text] [Related]
13. "Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial".
Holoye PY
Cancer Treat Rep; 1987 Apr; 71(4):431-2. PubMed ID: 3030548
[No Abstract] [Full Text] [Related]
14. [Cancer of the lung. New perspectives in medical treatment].
Gallo Curcio C
Arch Monaldi Mal Torace; 1989; 44(4-6):781-90. PubMed ID: 2577795
[No Abstract] [Full Text] [Related]
15. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
[TBL] [Abstract][Full Text] [Related]
16. Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2006 Jun; 7(6):565-73. PubMed ID: 16784028
[TBL] [Abstract][Full Text] [Related]
17. Prospects for pirarubicin.
Miller AA; Salewski E
Med Pediatr Oncol; 1994; 22(4):261-8. PubMed ID: 8107658
[No Abstract] [Full Text] [Related]
18. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
[TBL] [Abstract][Full Text] [Related]
19. Can weight loss at presentation predict patient outcome in lung cancer?
Temel J
Nat Clin Pract Oncol; 2004 Dec; 1(2):68-9. PubMed ID: 16264819
[No Abstract] [Full Text] [Related]
20. Clinical and molecular responses in lung cancer patients receiving Romidepsin.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Kruchin E; Wright JJ; Rosing DR; Sparreboom A; Figg WD; Steinberg SM
Clin Cancer Res; 2008 Jan; 14(1):188-98. PubMed ID: 18172270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
